This GLP-1 receptor agonist study will test the efficacy and safety of liraglutide in the treatment of people with idiopathic Parkinson's (of no known cause). The trial is taking place at the Cedars-Sinai Medical Center, Los Angeles, California and was selected by the Linked Clinical Trials committee and is and co-funded by The Cure Parkinson's Trust and the Van Andel Institute.

This single centre, double-blind, placebo-controlled study will enroll 57 participants. Subjects enrolled in the study will be randomised to receive once daily self-administered injections of liraglutide or placebo at the same dose range in a 2:1 study design.

Liraglutide has been approved by the Food and Drug Administration (FDA) to treat adults with Type 2 Diabetes and to treat obesity, but it is considered investigational in this study, as it has not yet been approved for use in people with Parkinson's. Liraglutide belongs to a class of medications able to stimulate receptors of glucagon-like peptide 1 (GLP-1), a naturally occurring peptide found throughout much of the brain and able to increase the gut hormone 'incretin' effect in diabetes stimulating the release of insulin. Liraglutide can reduce systemic and brain insulin resistance, an abnormality that could help drive Parkinson's pathogenesis. Indeed, impaired insulin signaling in the brain can cause or exacerbate many brain pathologies and behavioral abnormalities seen in PD. Another GLP-1 agonist, exenatide, has been trialled in people with PD, showing significant improvement of motor and cognitive symptoms. There is reason to believe that liraglutide may prove superior to exenatide in treating PD.

Eligible participants will be followed for up to 14 months and will be assessed by changes in the MDS-UPDRS and non-motor symptoms after 52 weeks of treatment. 

Source: Fox Trial Finder - The Michael J Fox Foundation Trial 4920